An American Cancer Society Guide for Informed Choices Downloaded from Colleen Doyle, MS, RD; Lawrence H
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
PCHHAX Overview of Flaxseed Patent
Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(14):33-38 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Overview of Flaxseed Patent Applications for the prevention and treatment of human cancer Sepideh Miraj Infertility Fellowship, Medicinal Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran _____________________________________________________________________________________________ ABSTRACT Flaxseed, Linum usitatissimum, is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world. The aim of this study is to overview its anti-cancer and anti-tumor effects. This review article was carried out by searching studies in PubMed, Medline, Web of Science, and IranMedex databases up to 2016.totally, of 1 08 found articles, 41 articles were included. The search terms were “Flaxseed. ”, “therapeutic”, “pharmacological”, anticancer, anti-tumor. Various studies have shown that Flaxseed. Possess Anti-Breast Cancer properties, Anti-Breast tumors properties , Anti-Ovary cancer properties, Gut-associated diseases properties, Lung tumor properties, Inflammation properties, Anti-Skin Carcinogenesis properties, Pro- carcinogenic, Mastalgia properties, Aortic remodeling ,Anti-mammary Cancer effect ,Antioxidant and Antiproliferative ,Colon cancer properties, Esophagitis properties, Apoptosis properties. Flaxseed possess lots of therapeutic and pharmacological effects.in this study, its anticancer, anti-tumor effects was overviewed. Keywords : Flaxseed, therapeutic, pharmacological, anticancer, anti-tumor. _____________________________________________________________________________________________ INTRODUCTION It is proved that herbal medicine is effective in the treatment of many diseases [1-10].Flax, Linum usitatissimum , is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world. -
A Bibliometric Analysis
787 Original Article Page 1 of 9 The 100 most cited articles on lung cancer screening: a bibliometric analysis Meng Li1,2, Qiang Cai2,3, Jing-Wen Ma1, Li Zhang1,2, Claudia I. Henschke2 1Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Department of Radiology, Mount Sinai Health System, New York, NY, USA; 3Department of Radiology, Shanxi Provincial People’s Hospital, Taiyuan, China Contributions: (I) Conception and design: M Li, CI Henschke; (II) Administrative support: CI Henschke; (III) Provision of study materials or patients: M Li, CI Henschke; (IV) Collection and assembly of data: M Li, L Zhang; (V) Data analysis and interpretation: M Li, Q Cai, JW Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Claudia I. Henschke. Department of Radiology, Mount Sinai Health System, 1 Gustave Levy Place, New York, NY 10029, USA. Email: [email protected]. Background: The number of citations of an article reflects its impact on the scientific community. The aim of this study was to identify and characterize the 100 most cited articles on lung cancer screening. Methods: The 100 most cited articles on lung cancer screening published in all scientific journals were identified using the Web of Science database. Relevant data, including the number of citations, publication year, publishing journal and impact factor (IF), authorship and country of origin, article type and study design, screening modality, and main topic, were collected and analyzed. Results: The 100 most cited articles were all English and published between 1973 and 2017, with 81 published after 2000. -
Cancer Treatment and Survivorship Facts & Figures 2019-2021
Cancer Treatment & Survivorship Facts & Figures 2019-2021 Estimated Numbers of Cancer Survivors by State as of January 1, 2019 WA 386,540 NH MT VT 84,080 ME ND 95,540 59,970 38,430 34,360 OR MN 213,620 300,980 MA ID 434,230 77,860 SD WI NY 42,810 313,370 1,105,550 WY MI 33,310 RI 570,760 67,900 IA PA NE CT 243,410 NV 185,720 771,120 108,500 OH 132,950 NJ 543,190 UT IL IN 581,350 115,840 651,810 296,940 DE 55,460 CA CO WV 225,470 1,888,480 KS 117,070 VA MO MD 275,420 151,950 408,060 300,200 KY 254,780 DC 18,750 NC TN 470,120 AZ OK 326,530 NM 207,260 AR 392,530 111,620 SC 143,320 280,890 GA AL MS 446,900 135,260 244,320 TX 1,140,170 LA 232,100 AK 36,550 FL 1,482,090 US 16,920,370 HI 84,960 States estimates do not sum to US total due to rounding. Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Contents Introduction 1 Long-term Survivorship 24 Who Are Cancer Survivors? 1 Quality of Life 24 How Many People Have a History of Cancer? 2 Financial Hardship among Cancer Survivors 26 Cancer Treatment and Common Side Effects 4 Regaining and Improving Health through Healthy Behaviors 26 Cancer Survival and Access to Care 5 Concerns of Caregivers and Families 28 Selected Cancers 6 The Future of Cancer Survivorship in Breast (Female) 6 the United States 28 Cancers in Children and Adolescents 9 The American Cancer Society 30 Colon and Rectum 10 How the American Cancer Society Saves Lives 30 Leukemia and Lymphoma 12 Research 34 Lung and Bronchus 15 Advocacy 34 Melanoma of the Skin 16 Prostate 16 Sources of Statistics 36 Testis 17 References 37 Thyroid 19 Acknowledgments 45 Urinary Bladder 19 Uterine Corpus 21 Navigating the Cancer Experience: Treatment and Supportive Care 22 Making Decisions about Cancer Care 22 Cancer Rehabilitation 22 Psychosocial Care 23 Palliative Care 23 Transitioning to Long-term Survivorship 23 This publication attempts to summarize current scientific information about Global Headquarters: American Cancer Society Inc. -
Integrative Oncology from a Bibliometric Point of View T Jenny-Ann Brodin Danell
Complementary Therapies in Medicine 52 (2020) 102477 Contents lists available at ScienceDirect Complementary Therapies in Medicine journal homepage: www.elsevier.com/locate/ctim Integrative oncology from a bibliometric point of view T Jenny-Ann Brodin Danell Department of Sociology, Umeå University, 901 87 Umeå, Sweden ARTICLE INFO ABSTRACT keywords: Objectives: The aim of this article is to analyze the development of integrative oncology from a bibliometric point Integrative oncology of view. The publication and citation patterns of publications are analyzed and their contents mapped. Complementary therapies Design: This study is based on bibliometric methods. The data sets consist of 7 025 respectively 4 990 pub- Research domain lications over the time period 1966-2016, shown in PubMed and Web of Science. Bibliometric methods Results: The expansion of the numbers of these publications took place in the late 1990s/early 2000s. Research is Citation analysis dominated by authors located in the USA, China and Germany who are working at well-established research Content analysis universities and university hospitals. The clinical share of publications is relatively small, and few studies are classified according to clinical phase. Content analysis revealed that much of the clinical research is based on surveys, and that content reflects the intersection of complementary therapies and cancer research. The latter aspect is less obvious in pre-clinical research. The most frequent journals in the material show a focus on complementary and alternative therapies or on integrative oncology, although journals focused on oncology or general/internal medicine were well-represented in the material as a whole. The most-cited publications were review articles and surveys. -
Unconventional Cancer Treatments
Unconventional Cancer Treatments September 1990 OTA-H-405 NTIS order #PB91-104893 Recommended Citation: U.S. Congress, Office of Technology Assessment, Unconventional Cancer Treatments, OTA-H-405 (Washington, DC: U.S. Government Printing Office, September 1990). For sale by the Superintendent of Documents U.S. Government Printing OffIce, Washington, DC 20402-9325 (order form can be found in the back of this report) Foreword A diagnosis of cancer can transform abruptly the lives of patients and those around them, as individuals attempt to cope with the changed circumstances of their lives and the strong emotions evoked by the disease. While mainstream medicine can improve the prospects for long-term survival for about half of the approximately one million Americans diagnosed with cancer each year, the rest will die of their disease within a few years. There remains a degree of uncertainty and desperation associated with “facing the odds” in cancer treatment. To thousands of patients, mainstream medicine’s role in cancer treatment is not sufficient. Instead, they seek to supplement or supplant conventional cancer treatments with a variety of treatments that exist outside, at varying distances from, the bounds of mainstream medical research and practice. The range is broad—from supportive psychological approaches used as adjuncts to standard treatments, to a variety of practices that reject the norms of mainstream medical practice. To many patients, the attractiveness of such unconventional cancer treatments may stem in part from the acknowledged inadequacies of current medically-accepted treatments, and from the too frequent inattention of mainstream medical research and practice to the wider dimensions of a cancer patient’s concerns. -
Web of Science™ Core Collection Current Contents Connect®
WEB OF SCIENCE™ CORE COLLECTION CURRENT CONTENTS CONNECT® XML USER GUIDE March, 2020 Table of Contents Overview 3 Support and Questions 4 Selection Criteria 5 XML Schemas 7 Schema Diagram 8 Source Record Identifiers 9 Document and Source Titles 11 Source Author Names 12 Full Names and Abbreviations 13 Chinese Author Names 13 Authors and Addresses 15 Research and Reprint Addresses 17 Organizations 18 Contributors 19 Cited References 21 Citations to Articles from Journal Supplements 22 Issue Information in the Volume Field 23 Cited Authors in References to Proceedings and Patents 23 © 2020 Clarivate Analytics 1 Counting Citations 24 Times Cited File 25 Delivery Schedule 26 Corrections and Gap Records 27 Deletions 28 Journal Lists and Journal Changes 29 Appendix 1 Subject Categories 30 Subject Catagories (Ascatype) 30 Web of Science™ Core Collection Subject Areas (Traditional Ascatype) 30 Research Areas (Extended Ascatype) 34 Current Contents Subject Codes 38 Current Contents Editions and Subjects 38 Appendix 2 Document Types 43 Document Types 43 Web of Science Core Collection Document Types 43 Current Contents Connect Document Types 44 Appendix 3 Abbreviations and Acronyms 46 Address Abbreviations 46 Country Abbreviations 51 Cited Patent Country Abbreviations 57 © 2020 Clarivate Analytics 2 Overview Your contract for raw data entitles you to get timely updates, which you may store and process according to the terms of your agreement. The associated XML schemas describe the record structure of the data and the individual elements that define -
American Society for Colposcopy and Cervical Pathology
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer Debbie Saslow, PhD,1 Diane Solomon, MD,2 Herschel W. Lawson, MD,3 Maureen Killackey, MD,4 Shalini L. Kulasingam, PhD,5 Joanna Cain, MD, FACOG,6 Francisco A. R. Garcia, MD, MPH,7 Ann T. Moriarty, MD,8 Alan G. Waxman, MD, MPH,9 David C. Wilbur, MD,10 Nicolas Wentzensen, MD, PhD, MS,11 Levi S. Downs, Jr, MD,12 Mark Spitzer, MD,13 Anna-Barbara Moscicki, MD,14 Eduardo L. Franco, DrPH,15 Mark H. Stoler, MD,16 Mark Schiffman, MD,17 Philip E. Castle, PhD, MPH,18* and Evan R. Myers, MD, MPH19* 1Director, Breast and Gynecologic Cancer, Cancer Control Science Department, American Cancer Society, Atlanta, GA, on behalf of the Steering Committee, Data Group, and Writing Committee; 2Senior Investigator, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, on behalf of the Steering Committee; 3Adjunct Associate Professor, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, on behalf of the Data Group; 4Deputy Physician in Chief, Medical Director, Memorial Sloan-Kettering Cancer Center Regional Network, Department of Surgery, Gynecology Service, Memorial Sloan-Kettering Cancer Center, Correspondence to: Debbie Saslow, PhD, Director, Breast and Gyneco- Disclaimers: The contents of the paper are solely the responsibility of logic Cancer, American Cancer Society, 250 Williams St NW, Suite 600, the authors and do not necessarily represent the official views of the Atlanta, GA 30303. -
Legislative Scorecard 2019
American Cancer Society Cancer Action Network Legislative Scorecard 2019 fightcancer.org American Cancer Society Cancer Action Network Legislative Scorecard 2019 The American Cancer Society Cancer Action Network (ACS CAN) Other legislation ACS CAN supported in 2019 that was passed empowers cancer patients, survivors, their families and other and enacted included reducing cancer-causing pollution health advocates by amplifying their voices in the halls of from medium- and heavy-duty vehicles by reducing the level government. As such, ACS CAN is a powerful force in shaping of greenhouse gas emissions allowed, as well as improving policies that fight cancer. We mobilize our large grassroots emission standards. Another bill we championed will require network to elevate cancer as a priority with lawmakers at the manufacturers of cosmetic products to disclose potentially local, state and federal levels. cancer-causing ingredients on a public website. In California, ACS CAN and its volunteer advocates influence On the tobacco control front, ACS CAN and its volunteer evidence-based legislation and regulatory solutions that will advocates were tireless in spotlighting the influence of the reduce the cancer burden. As the American Cancer Society’s tobacco industry at the Capitol and in particular Juul Labs, nonprofit, nonpartisan advocacy affiliate, ACS CAN is critical to which the Federal Drug Administration (FDA) says is behind a the fight for a world without cancer. nationwide youth e-cigarette epidemic. While Congress and the courts considered changes to the health New data from the FDA in 2019 showed that the youth use care law in 2019 that would decrease enrollment in health of e-cigarettes in high school is skyrocketing, with a 135% exchanges fostered by the landmark Affordable Care Act, ACS CAN increase over the past two years. -
November 4, 2009
Senate Senate Chamber Room E3-262 Engineering Building WEDNESDAY, November 4,2009 1:30 p.m. Regrets call 474-6892 AGENDA MATTERS TO BE CONSIDERED IN CLOSED SESSION 1. Report of the Senate Committee on Honorary Degrees This report will be distributed at the Senate meeting. Copies will be available for inspection by members of Senate in the Office of the University Secretary on the day preceding the Senate meeting. II MATTERS RECOMMENDED FOR CONCURRENCE WITHOUT DEBATE 1. Report of the Executive Committee of the Faculty of Graduate Studies on Course and Curriculum Changes RE: Masters of Physician Assistant Studies program, the Department of Microbiology, the Asper School MBA, and the Departments of Economics, History, and Psychology Page 17 III MATTERS FORWARDED FOR INFORMATION 1. Report of the Senate Committee on Awards Page 24 2. In Memoriam: Professor Lew Layman Page 30 3. Report on Research Contract Funds Received Page 32 January 1, 2009 to June 30, 2009 4. Items approved by the Board of Governors Page 37 September 29, 2009 5. Correspondence from the Senate Committee on Page 38 University Research RE: Establishment of the Experimental Media Research Group IV ELECTION OF SENATE REPRESENTATIVES 1. Election of a Student Member to the Senate Executive Committee Page 44 V REPORT OF THE PRESIDENT VI QUESTION PERIOD Senators are reminded that questions shall normally be submitted in writing to the University Secretary no later than 10:00 a.m. of the day preceding the meeting. VII CONSIDERATION OF THE MINUTES OF THE MEETING OF OCTOBER 7,2009 CONSIDERATION OF THE MINUTES OF THE MEETING OF JUNE 24, 2009 VIII BUSINESS ARISING FROM THE MINUTES IX REPORTS OF THE SENATE EXECUTIVE COMMITTEE AND THE SENATE PLANNING AND PRIORITIES COMMITTEE 1. -
What Is the Relay for Life Movement? Join the W Orldwide
What is the Relay For Life movement? Join the worldwide movement to end cancer. end to movement worldwide Join the Each American Cancer Society Relay For Life event gives everyone an opportunity to fight cancer and help save more lives. Teams made up of family members, friends, and/or coworkers camp out at a local school, park, or fairground and take turns walking American Cancer Society Relay For Life | RelayForLife.org 1.800.227.2345 around a track or path. Because cancer never sleeps, each team is asked to have a representative on the track at all times during the overnight event. Relay For Life is the signature fundraising event for the American Cancer Society. At the event, you will have the opportunity to celebrate cancer survivors, remember loved ones lost to the disease, and learn more about how to fight back against cancer. While you’re raising much-needed funds, you’ll also be raising awareness of the importance of cancer prevention, early detection, treatment, and patient support. Celebrate Survivors and Caregivers At Relay For Life events, cancer survivors and caregivers can come together and be recognized for their personal fight against a disease that has taken too much. In addition to a special ceremony, Survivors and Caregivers laps open the event and serve as a testament to the fight against cancer and the hope for a cure. All survivors and caregivers are invited to join their local Relay For Life event, no matter where their personal journey with cancer has taken them. Remember during the Luminaria Ceremony When the sun goes down, luminaria line the track, each one lit in honor or memory of those who have faced cancer – those who lost their battle, those who won, and those whose fight continues. -
Cancer Facts for Women
cancer.org | 1.800.227.2345 Cancer Facts for Women Some of the cancers that most often affect women are breast, colorectal, endometrial, lung, cervical, skin, and ovarian cancers. Knowing about these cancers and what you can do to help prevent them or find them early (when they are small, haven't spread, and might be easier to treat) may help save your life. Breast cancer Breast cancer1 is the most common cancer in American women, except for skin cancers. It can occur at any age, but the risk goes up as you get older. Because of certain factors, some women may have a greater chance of having breast cancer than others. But every woman should know about the risks for breast cancer and what they can do to help lower their risk. What you can do Finding breast cancer early – when it’s small, has not spread, and might be easier to treat – can help prevent deaths from the disease. Getting regular screening tests is the most reliable way to find breast cancer early. The American Cancer Society recommends the following for women at average risk for breast cancer: Women ages 40 to 44 should have the choice to start yearly breast cancer screening with a mammogram (x-ray of the breast) if they wish to do so. Women age 45 to 54 should get a mammogram every year. Women 55 and older can switch to a mammogram every 2 years, or can continue yearly screening. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Screening should continue as long as a woman is in good health and is expected to live at least 10 more years. -
What Happens When a Journal Converts to Open Access? a Bibliometric Analysis
What happens when a journal converts to Open Access? A bibliometric analysis Fakhri Momeni1*, Philipp Mayr1,2*, Nicholas Fraser 3* and Isabella Peters4 1 [email protected] GESIS – Leibniz Institute for the Social Sciences, Unter Sachsenhausen 6-8, 50667 Cologne (Germany) [email protected] Institute of Computer Science, University of Göttingen, (Germany) 3 [email protected], [email protected] ZBW – Leibniz Information Centre for Economics, Düsternbrooker Weg 120, 24105 Kiel (Germany) * Correspondence: [email protected], [email protected] and [email protected] Abstract In recent years, increased stakeholder pressure to transition research to Open Access has led to many journals converting, or ‘flipping’, from a closed access (CA) to an open access (OA) publishing model. Changing the publishing model can influence the decision of authors to submit their papers to a journal, and increased article accessibility may influence citation behaviour. In this paper we aimed to understand how flipping a journal to an OA model influences the journal’s future publication volumes and citation impact. We analysed two independent sets of journals that had flipped to an OA model, one from the Directory of Open Access Journals (DOAJ) and one from the Open Access Directory (OAD), and compared their development with two respective control groups of similar journals. For bibliometric analyses, journals were matched to the Scopus database. We assessed changes in the number of articles published over time, as well as two citation metrics at the journal and article level: the normalised impact factor (IF) and the average relative citations (ARC), respectively.